Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen

Current Opinion in Investigational Drugs

Volumn 11, Issue 5, 2010, Pages 586-596

  Larenas Linnemann, Désirée ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; COLECALCIFEROL; CORTICOSTEROID; GRASS POLLEN VACCINE; ORALAIR; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; APPENDICITIS; BIRCH; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG WITHDRAWAL; EAR PRURITUS; ENDOMETRIOSIS; HEADACHE; HEMORRHOID; HUMAN; HYPESTHESIA; HYPOTENSION; IMMUNOTHERAPY; NONHUMAN; OCULAR PRURITUS; ORAL BLISTER; ORAL HYPOESTHESIA; OROPHARYNGEAL PRURITUS; PHARYNGITIS; PHARYNX EDEMA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SIDE EFFECT; SKIN TEST; SNEEZING; STROKE; TABLET; TABLET FORMULATION; THROAT IRRITATION; TONGUE SWELLING; URTICARIA;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ANTIGENS, PLANT; BETULA; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; POLLEN; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; TABLETS;

EID: 77952232284     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Bomay and Stallergenes have signed a patent licence agreement. Laboratoire de Stallergenes SA PRESS RELEASE 2003 May 12
2. Annual report 2003: Stallergenes. Laboratoire de Stallergenes SA ANNUAL REPORT 2004 May 12
3. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Batard T, Didierlaurent A, Chabre H, Mothes N, Bussieres L, Bohle B, Couret MN, Ball T, Lemoine P, Tejkl MF, Chenal A et al INT ARCH ALLERGY IMMUNOL 2005 136 3 239-249
4. Stallergenes and Paladin Labs sign a partnership for Oralair in Canada. Stallergenes SA PRESS RELEASE 2007 January 10
5. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT-study. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Moller C et al ALLERGY 2007 62 8 943-948
6. Stallergenes signs an exclusive partnership agreement with Solvay Pharmaceuticals for the promotion and distribution of its products in Russia and the CIS Stallergenes SA PRESS RELEASE 2009 March 24
7. Stallergenes: 2008: Strong performance. Stallergenes SA PRESS RELEASE 2009 March 24
8. American Academy of Allergy Asthma and Immunology (AAAAI) - 2009 Annual meeting (Part II), Washington DC, USA, 13-17 march 2009. Bielory L IDDB MEETING REPORT 2009 March 13-17
9. American Academy of Allergy Asthma and Immunology (AAAAI) - 2009 Annual meeting (Part III), Washington DC, USA, 13-17 march 2009. Broide D IDDB MEETING REPORT 2009 March 13-17
10. Stallergenes S. A.: Positive results from a phase IIb/III clinical trial on the house dust mite desensitization tablet. Stallergenes SA PRESS RELEASE 2009 April 29
11. Safety and tolerability of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT). Winther L, Poulsen L, Robin B, Melac M, Malling H ALLERGY 2009 64 Suppl 90 Abs 341 •• reports combined results from two phase I clinical trials (NCT00889460; VO58.07 DK and NCT00396149; VO49.06 DK) that assessed Oralair Birch (12.5 to 300 μg slIT, qd for 2 weeks except weekends) in patients (n = 112) with symptomatic birch pollen allergy. In the treated patient cohort (n = 84), birch and/or Bet v 1 IgE and IgG4 serum antibody titers increased by 82 and 36% from baseline, respectively. In patients evaluable for safety (n = 101), Oralair Birch was well tolerated up to doses of 50 μg and, in contrast, incremental doses of < 100 μg or single doses of 150 μg were not well tolerated. Patients who received Oralair Birch treatment reported treatmentemergent adverse events that were SLIT related including oropharyngeal pruritis, ear pruritis, rhinitis and pharyngeal edema.
12. Stallergenes: Immunotherapy tablet containing recombinant allergen (rBet v 1) of Birch pollen: Positive results for a phase IIb/III trial. Stallergenes SA PRESS RELEASE 2009 September 16
13. NCT00901914: Study of rBet v1 tablets. Stallergenes SA CLINICALTRIALS. GOV 2009 May 13
14. Subcutaneous immunotherapy with recombinant Bet v 1 in birch allergy: Clinical and immunological effects. Pauli G, Malling H, Rak S, Horak F, Pastorello E, Purohit A, Holst-Larsen T, Arvidsson M, Mothes N, Kavina A, Szaal S et al ALLERGY 2007 62 83 Abs 706
15. Characterization of recombinant Bet v 1 as a candidate vaccine against birch pollen allergy. Nony E, Chabre H, Lautrette A, Lemoine P, Couret M, Bobinnec Y, Didierlaurent A, Batard T, Moingeon P ALLERGY 2008 63 Suppl 88 Abs 599
16. Standardization of allergen products: 1. Detailed characterization of GmP-produced recombinant Bet v 1.0101 as biological reference preparation. Himly M, Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R, Buchheit KH, Vieths S, Moingeon P, Ferreira F ALLERGY 2009 64 7 1038-1045 •• reports the characterization of an rBet v 1.0101 produced in accordance to GMP for the Biological standardization Program of the EDQM. The rBet V 1.0101 was 159 amino acids long and had 96.2% sequence identity with a major Bet v 1a pollen allergen record held in the swiss-Prot protein sequence database (primary accession number: P15494). The rBet v 1.0101 protein was monomeric and stable when tested for up to 3 months at 4°C. In functional assays, rBet V 1.0101 exhibited allergenic potency. The EDQM selected rBet v 1.0101 as an international reference material for studies required during the clinical application of allergenic drug candidates such as Oralair Birch.
17. High throughput screening of mixed-mode sorbents and optimization using pre-packed lab-scale columns for the purification of the recombinant allergen rBet v 1a. Brochier VB, Chabre H, Lautrette A, Ravault V, Couret MN, Didierlaurent A, Moingeon P J CHROMATOGR B ANAL TECHNOL BIOMED LIFE SCI 2009 877 24 2420-2427
18. Patterns of IgE, IgG, and skin tests responses to Bet v 1 and birch pollen extract after immunotherapy with recombinant Bet v 1. Pauli G, Larsen T, Rak S, Horak F, Spitzauer S, Mothes N, Purohit A, Pastorello E, Arvidsson M, Kavina A, Schroeder J et al ALLERGY 2008 63 Suppl 88 Abs 488
19. Assessing purity and integrity of pharmaceutical grade rBet v 1 using rapid separation liquid chromatography combined with on-line ultra-high resolution time of flight mass spectrometry. Emmanuel N, Godat E, Lemoine P, Batard T, Didierlaurent A, Moingeon P ALLERGY 2009 64 Suppl 90 Abs 227
20. Safety and tolerability of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT). Winther L, Poulsen LK, Robin B, Melac M, Malling H J ALLERGY CLIN IMMUNOL 2009 123 2 Suppl 1 Abs 828
21. The European Union biological standardization program: Detailed characterization of GmP-produced recombinant Bet v 1.0101 and Phi P 5.0109 as candidate reference standards. Himly M, Neubauer A, Moingeon P, Cromwell O, van Ree R, Buchheit K, Vieths S, Ferreira F J ALLERGY CLIN IMMUNOL 2009 123 2 Abs 831
22. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N et al J ALLERGY CLIN IMMUNOL 2008 122 5 951-960 •• Reports results from a completed phase II clinical trial (NCT00410930; DV08.01) that assessed rBet v 1, a licensed birch pollen extract and nBet v 1 (0 to 15 μg each allergen, SCIT weekly for 12 weeks, then 15 μg sCIT monthly for 2 years) in patients (n = 147) with birch pollen-related rhinoconjunctivitis and/or mild asthma. Treatment with all three allergens significantly reduced the occurrence of rhinoconjunctivitis symptoms, skin sensitivity and the use of rescue and controller medications observed by patients compared with a placebo group. After 1 and 2 years of treatment the levels of Bet v 1-specific IgG and IgG subclasses (IgG1, IgG2 and IgG4) were increased in all treated groups, while no changes in Bet v 1-specific IgGE, IgA or IgG3 observed.
23. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I et al ALLERGY 2008 63 Suppl 86 8-160 (Pubitemid 351357811)
24. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE ALLERGY 2006 61 2 198-201
25. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. DesRoches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J J ALLERGY CLIN IMMUNOL 1997 99 4 450-453
26. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: Clinical efficacy and more. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G ALLERGY 2004 59 11 1205-1210
27. Preventive effects of sublingual immunotherapy in childhood: An open randomized controlled study. Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco ADR, Canonica GW, Passalacqua G, Tripodi S ANN ALLERGY ASTHMA IMMUNOL 2008 101 2 206-211
28. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ J ALLERGY CLIN IMMUNOL 2008 121 5 1120-1125
29. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C J ALLERGY CLIN IMMUNOL 2007 120 3 707-713
30. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Schiappoli M, Ridolo E, Senna G, Alesina R, Antonicelli L, Asero R, Costantino MT, Longo R, Musarra A, Nettis E, Crivellaro M et al CLIN EXP ALLERGY 2009 39 10 1569-1574
31. Side-effects of allergen-specific immunotherapy: A prospective multi-centre study. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H CLIN EXP ALLERGY 2006 36 3 254-260
32. Evaluation of near-fatal reactions to allergen immunotherapy injections. Amin HS, Liss GM, Bernstein DI J ALLERGY CLIN IMMUNOL 2006 117 1 169-175
33. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. Bernstein DI, Wanner M, Borish L, Liss GM J ALLERGY CLIN IMMUNOL 2004 113 6 1129-1136
34. Comparative analysis of nasal and oral mucosa dendritic cells. Allam JP, Niederhagen B, Bucheler M, Appel T, Betten H, Bieber T, Berge S, Novak N ALLERGY 2006 61 2 166-172
35. Distribution of Langerhans cells and mast cells within the human oral mucosa: New application sites of allergens in sublingual immunotherapy? Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N ALLERGY 2008 63 6 720-727
36. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Calderon MA, Birk AO, Andersen JS, Durham SR ALLERGY 2007 62 8 958-961
37. Sublingual immunotherapy in children: Complete and updated review supporting evidence of effect. Larenas-Linnemann D CURR OPIN ALLERGY CLIN IMMUNOL 2009 9 2 168-176
38. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S J ALLERGY CLIN IMMUNOL 2006 117 4 802-809
39. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, Andre C, de Beaumont O, Melac M J ALLERGY CLIN IMMUNOL 2007 120 6 1338-1345
40. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T ALLERGY 2002 57 5 423-430
41. Purification and characterization of recombinant Bet v I, the major birch pollen allergen - Immunological equivalence to natural Bet v 1. Ferreira FD, Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C, Sommergruber W, Steiner R, Bohle B, Sperr WR, Valent P, Kungl AJ et al J BIOL CHEM 1993 268 26 19574-19580
42. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies. Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, Ferreira F, Kraft D, Valenta R J ALLERGY CLIN IMMUNOL 1996 97 5 1100-1109
43. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, Mistrello G, Canonica GW J ALLERGY CLIN IMMUNOL 1997 100 1 122-129
44. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani P, Mistrello G, Canonica GW, Mariani G CLIN EXP ALLERGY 2001 31 1 54-60
45. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H INT ARCH ALLERGY IMMUNOL 2008 145 3 193-206
46. Allergy multivaccines created by DNA shuffing of tree pollen allergens. Wallner M, Stocklinger A, Thalhamer T, Bohle B, Vogel L, Briza P, Breiteneder H, Vieths S, Hartl A, Mari A, Ebner C et al J ALLERGY CLIN IMMUNOL 2007 120 2 374-380
47. A novel approach to specific allergy treatment: The recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. Gerstmayr M, Ilk N, Schabussova I, Jahn-Schmid B, Egelseer EM, Sleytr UB, Ebner C, Bohle B J IMMUNOL 2007 179 11 7270-7275
48. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: A randomized, placebocontrolled, double-blind, double-dummy study. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ ALLERGY 2004 59 1 45-53 (Pubitemid 38167951)
49. -2009 Financial results. Stallergenes SA PRESS RELEASE 2010 March 16
50. Comparison of in vivo allergenic activity of recombinant Bet v 1 with allergen-specific in vitro immune responses in birch pollen allergic patients. Mothes-Luksch N, Spitzauer S, Hauswirth A, Krauth M, Valent P, Steiner R, Didierlaurent A, Broutin O, Brillard C, Combebias A, Galvain S et al CONGR EUR ACAD ALLERGY CLIN IMMUNOL 2006 Abs 1056 • reports results from a clinical trial that assessed rBet v 1, nBet v 1 and birch pollen extract by skin prick tests in patients (n = 25) with birch pollen allergy; after skin prick testing with allergens in evaluable patients, the level of serum IgE antibodies, basophil activation and skin responses were associated but the magnitude of the each response was not well correlated. The lack of correlation was not explained by the levels of serum IgG or Iga antibodies against nBet v 1, IFNγ or Il-10 production by allergen-stimulated PBMC in vitro.
51. The European Community Respiratory Health Survey: What are the main results so far? Janson C, Anto J, Burney P, Chinn S, de Marco R, Heinrich J, Jarvis D, Kuenzli N, Leynaert B, Luczynska C, Neukirch F et al EUR RESPIR J 2001 18 3 598-611
52. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S THORAX 2009 64 6 476-483
53. What have we learnt from ISAAC phase III in the Asia-Pacific rim? Fok AOL, Wong GWK CURR OPIN ALLERGY CLIN IMMUNOL 2009 9 2 116-122
54. Allergy diagnostic testing: An updated practice parameter. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, Sicherer S, Golden DBK, Khan DA, Nicklas RA, Portnoy JM et al ANN ALLERGY ASTHMA IMMUNOL 2008 100 3 S1-S148
55. The diagnosis and management of rhinitis: An updated practice parameter. Wallace DV, Dykewicz MS, Bernstein DI, Bernstein IL, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM et al J ALLERGY CLIN IMMUNOL 2008 122 2 S1-S84 (Pubitemid 352033573)
56. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D ALLERGY 2007 62 3 301-309
57. Identification of profilin as an actin-binding protein in higher-plants. Valenta R, Ferreira F, Grote M, Swoboda I, Vrtala S, Duchene M, Deviller P, Meagher Rb, Mckinney E, Heberlebors E, Kraft D et al J BIOL CHEM 1993 268 30 22777-22781
58. Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy. Weber RW J ALLERGY CLIN IMMUNOL 2008 122 1 219-221
59. Allergen immunotherapy: Where is it now? Nelson HS J ALLERGY CLIN IMMUNOL 2007 119 4 769-777
60. Allergen immunotherapy: A practice parameter second update. J ALLERGY CLIN IMMUNOL 2007 120 3 Suppl S25-S85
61. Prophylactic inoculation against hay fever. Noon L LANCET 1911 177 4580 1572-1573
62. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Freeman J LANCET 1911 178 4594 814-817
63. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. Vrtala S, Sperr Wr, Reimitzer I, Vanree R, Laffer S, Muller Wd, Valent P, Lechner K, Rumpold H, Kraft D, Scheiner O et al J IMMUNOL 1993 151 9 4773-4781
64. Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. Breiteneder H, Ferreira F, Hoffmannsommergruber K, Ebner C, Breitenbach M, Rumpold H, Kraft D, Scheiner O EUR J BIOCHEM 1993 212 2 355-362
65. Characterization of recombinant bet v 1, the major pollen allergen of Betula verrucosa (white birch), produced by fed-batch fermentation. Nedergaard-Larsen J, Bou-Casals A, From NB, Stroman P, Ipsen H INT ARCH ALLERGY IMMUNOL 1993 102 3 249-258
66. How are Th2-type immune responses initiated and amplifed? William E P, Jinflang Z NAT REV IMMUNOL 2010 10 225-235
67. Age-dependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children. Silvestri M, Rossi GA, Cozzani S, Pulvirenti G, Fasce L ANN ALLERGY ASTHMA IMMUNOL 1999 83 4 335-340
68. The natural history of allergy: The development of new sensitizations in asthmatic children. Fasce L, Tosca MA, Olcese R, Milanese M, Erba D, Ciprandi G IMMUNOL LETT 2004 93 1 45-50
69. Allergen immunotherapy. Frew AJ J ALLERGY CLIN IMMUNOL 2010 125 Suppl 2 S306-S316
70. Standardization of allergen extracts for immunotherapy: Where do we stand? Becker WM, Vogel L, Vieths S CURR OPIN ALLERGY CLIN IMMUNOL 2006 6 6 470-475.